We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Syndax Pharmaceuticals
SNDX
$1.82B
| $5.02M | 0.04% |
240,010
-14,864
| -6% | -$309K |
|
327
Ford
F
$58.5B
| $5M | 0.04% |
330,563
-14,438
| -4% | -$183K |
|
328
CME Group
CME
$92.3B
| $4.93M | 0.04% |
26,622
-2,166
| -8% | -$400K |
|
329
Capital One
COF
$127B
| $4.92M | 0.04% |
45,019
-24,653
| -35% | -$2.47M |
|
330
BridgeBio Pharma
BBIO
$16.5B
| $4.9M | 0.04% |
285,000
| – | – |
|
|
INBX
331
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $4.86M | 0.04% |
187,069
| – | – |
|
332
Hasbro
HAS
$12.8B
| $4.85M | 0.04% |
46,520
+39,129
| +529% | +$2.28M |
|
333
Okta
OKTA
$23.9B
| $4.84M | 0.04% |
69,765
-1,734
| -2% | -$132K |
|
|
ATVI
334
DELISTED
Activision Blizzard
ATVI
| $4.83M | 0.03% |
57,272
-64,528
| -53% | -$5.22M |
|
335
Conagra Brands
CAG
$7.29B
| $4.81M | 0.03% |
142,734
-153,795
| -52% | -$5.55M |
|
336
Paychex
PAYX
$41.1B
| $4.81M | 0.03% |
43,020
+5,762
| +15% | +$630K |
|
337
Pliant Therapeutics
PLRX
$66.9M
| $4.8M | 0.03% |
265,000
+25,000
| +10% | +$592K |
|
338
Terex
TEX
$7.89B
| $4.68M | 0.03% |
+78,258
| New | +$3.88M |
|
339
Sherwin-Williams
SHW
$80.7B
| $4.66M | 0.03% |
17,535
-15,020
| -46% | -$3.54M |
|
340
Kinder Morgan
KMI
$70.6B
| $4.62M | 0.03% |
268,140
+1,060
| +0.4% | +$18K |
|
341
Hewlett Packard
HPE
$63.8B
| $4.55M | 0.03% |
270,938
-55,040
| -17% | -$842K |
|
342
Labcorp
LH
$24.7B
| $4.54M | 0.03% |
21,919
-19,764
| -47% | -$3.83M |
|
343
Target
TGT
$63.7B
| $4.46M | 0.03% |
33,791
-153,159
| -82% | -$22.7M |
|
|
K
344
DELISTED
Kellanova
K
| $4.41M | 0.03% |
69,611
-7,587
| -10% | -$484K |
|
345
Keurig Dr Pepper
KDP
$41B
| $4.4M | 0.03% |
140,758
-128,042
| -48% | -$4.2M |
|
346
Archer Daniels Midland
ADM
$40.1B
| $4.4M | 0.03% |
58,236
-31
| -0.1% | -$2.35K |
|
347
Ingersoll Rand
IR
$33.1B
| $4.36M | 0.03% |
66,723
-22,537
| -25% | -$1.33M |
|
348
FedEx
FDX
$73.5B
| $4.33M | 0.03% |
17,454
+1,013
| +6% | +$232K |
|
349
American International
AIG
$42B
| $4.3M | 0.03% |
74,814
-48,681
| -39% | -$2.61M |
|
350
Korn Ferry
KFY
$4.13B
| $4.29M | 0.03% |
86,536
-84,883
| -50% | -$4.18M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.